Astic, L., Saucier, D., Coulon, P., Lafay, F
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
Treatment decisions are based on individual evaluation, and results vary
Early diagnosis and treatment are important for dealing with gastroparesis well and avoiding problems. A woman filed a lawsuit against the drug makers for Ozempic and Mounjaro after experiencing severe gastrointestinal events, including gastroparesis, also known as stomach paralysis
Baseline HbA1c levels were also higher in the dulaglutide group (7.34 0.89 vs
Wetenschappelijke studies richten zich onder andere op incretinesignalering, receptoractivatie, intracellulaire signaaltransductie en de regulatie van glucosehomeostase binnen gecontroleerde onderzoeksmodellen